Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce the signing of a non-binding term sheet for potential funding of up to US$14.4 million. The funding is in collaboration with an affiliate of Helena Partners Inc., a Cayman-Islands-based advisor and investor.
The infusion of capital is expected to significantly bolster Filament Health's operations, particularly in advancing its drug development programs. Furthermore, this funding will play a crucial role in facilitating the completion of the Proposed Business Combination with the Jupiter Acquisition Corporation. Notably, it is a strategic step towards achieving the company's goal of listing on the Nasdaq stock exchange.
This financial boost demonstrates Filament Health's commitment to driving innovation in the pharmaceutical sector and expanding its presence in the financial markets. Stay tuned for more updates on Filament Health's exciting journey ahead.
Contact Details
Proactive Investors
+1 604-688-8158
